Artimplant postpones Annual General Meeting until June 27, 2013 and publishes the Annual Report of 2012.

The Board decided to put back the Annual General Meeting 2013 from May 30 to June 27, 2013. The ongoing company evaluation work by the Board regarding the structure of the company and ways to finance the company continues

The company publishes the Annual report 2012 on the company web page ;

http://www.artimplant.com/investors-media/arsredovisningar.html . The report will only be published in Swedish. The Annual Report can also be ordered from the company via investor.relations@artimplant.com or via telephone +46 31 746 5600. The audit report deviates from standard.


Västra Frölunda, April 29, 2013

Kjell Thörnbring
CEO

For further information, please contact:
Kjell Thörnbring, CEO
E-mail: kjell.thornbring@artimplant.com
Telephone: +46 703 119 025

Further information is available at www.artimplant.com where you can also subscribe to future press releases; www.artimplant.com/investors-media/subscribe-to-press-releases.html

Artimplant
Artimplant is a biomaterials company focused on solutions to problems in orthopedics. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon®, meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet as well as shoulder and other soft tissue injuries.

Artimplant is a public company, listed on NASDAQ OMX Stockholm in the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting on the Company's business, including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This is information that Artimplant will make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on April 29, 2013 at 1:45 pm (Swedish time).

About Us

Artimplant is a research- and development company, active within bio-materials.

Subscribe

Documents & Links